Another Symbicort Patent Revoked In EU
Half a year after a European appellate panel revoked the combination patent for AstraZeneca Plc's blockbuster drug Symbicort's asthma treatment, the same panel has revoked one of two combination patents detailing...To view the full article, register now.
Already a subscriber? Click here to view full article